Clinical Trial Update: Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon [Phase 2]

View source ↗

Summary

A Phase 2 dose-response study evaluating a topical nitroglycerin formulation for Raynaud's phenomenon has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon

Drugs mentioned

• Nitroglycerin topical formulation (nitroglycerin)

Snippet

Sponsor: MediQuest Therapeutics | Conditions: Raynaud's Disease | Phase 2 | Status: COMPLETED